Drug updated on 4/17/2024
| Dosage Form | Powder (inhalation; fluticasone furoate/ umeclidinium/ vilanterol; 100/62.5/25 mcg) Powder (inhalation; fluticasone furoate/ umeclidinium/ vilanterol; 200/62.5/25 mcg) |
| Drug Class | Inhaled corticosteroids and long-acting beta2-adrenergic agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
- For the maintenance treatment of asthma in patients aged 18 years and older.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) Prescribing Information. | 2023 | GlaxoSmithKline, Durham, NC |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical review report; fluticasone furoate, umeclidinium, and vilanterol (Trelegy Ellipta). | 2018 | CADTH |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| 2022 GINA report, global strategy for asthma management and prevention. | 2022 | GINA |
| Asthma guideline updates | 2022 | ACSAP: Pulmonary Care |